When treating patients who have achieved remission, it can be helpful to explain that a relatively small number of cancer cells remain in their body. This is called measurable residual disease, or MRD.12 As a clinician, you have most likely had the challenge of communicating the complexity ...
When treating patients who have achieved remission, it can be helpful to explain that a relatively small number of cancer cells remain in their body. This is called measurable residual disease, or MRD.11 As a clinician, you have most likely had the challenge of communicating the complexity ...
Background/Purpose: Treatment targets for RA do shift towards remission of disease activity. However, remission does not occur regularly in practice and the question may be raised what currently is the appropriate treatment target: remission or low disease activity? This is...
For example, to guide post-remission treatment for intermediate-risk patients where MRD positive patients receive allogeneic stem cell transplantation and MRD negative receive autologous stem cell transplantation. Other upcoming uses of MRD that are being investigated include: selecting the type of ...
ICLUSIG is a prescription medicine used to treat adults who have: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in combination with chemotherapy in newly diagnosed Ph+ ALL* alone in adults with Ph+ ALL who cannot receive any other kinase inhibitor medicines or who have a...
we see in a patient population that has poor 5-year overall survival and pretty limited responses to combination chemotherapy the complete remission and complete remission with incomplete count recovery rate exceeds 80%, and virtually all of those responses are minimal residual disease...
In addition to the above markers of Treg cells, there are many other molecules involved in their immunosuppressive function. CTLA-4 is a negative regulator of T cell activation that shares the molecular ligand CD80/CD86 with CD28 and has a higher affinity [42]. CD80/CD86 is expressed on matu...
reported the use of 89Zirconium-labelled atezolizumab in a cohort of patients with non-small-cell lung carcinoma (NSCLC), bladder cancer and triple negative breast cancer [90]. In this work, PET tumour uptake was better correlated to response rate and clinical responses than immunohistochemistry ...